Clinical Trial

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

Name: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) — clinical trial record (NCT06339008)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.

Protocol Amendment History 1 change

notable Trial sites expanded: 70 -> 77 locations 2026-04-21

Trial Details

NCT Number	NCT06339008
Lead Sponsor	Eli Lilly and Company
Conditions	Perennial Allergic Rhinitis (PAR)
Enrollment	450 participants
Start Date	2024-04-26
Primary Completion	2026-09 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-18